Sepsis And Severe Infection

SECTION 1

Historical Context & Motivation

The concept of sepsis has been recognized since antiquity, when Hippocrates described a process of biological decay that caused flesh to rot and wounds to fester. For centuries, clinicians attributed this phenomenon to miasma or imbalanced humors, and mortality from systemic infection remained devastatingly high. The modern understanding of sepsis as a dysregulated host response to infection emerged only after transformative advances in microbiology, immunology, and critical care medicine reshaped the landscape of acute care.

1914

Schottmüller's Definition

Hugo Schottmüller proposed that sepsis occurs when a focus of infection releases pathogens into the bloodstream, triggering systemic illness — one of the first formal clinical definitions.

1992

SIRS / Sepsis-1 Consensus

The ACCP/SCCM Consensus Conference introduced Systemic Inflammatory Response Syndrome (SIRS) criteria, defining sepsis as SIRS plus a documented or suspected infection. This framework dominated clinical practice for over two decades.

2001

Sepsis-2 Revised Criteria

An international task force expanded the diagnostic criteria beyond SIRS to include laboratory and hemodynamic variables, though SIRS criteria remained central to bedside screening.

2016

Sepsis-3 (Third International Consensus)

Sepsis was redefined as life-threatening organ dysfunction caused by a dysregulated host response to infection. The Sequential Organ Failure Assessment (SOFA) score replaced SIRS, and qSOFA was introduced for bedside screening.

2021

Surviving Sepsis Campaign Update

The SSC guidelines were updated to include a one-hour resuscitation bundle, dynamic assessment of fluid responsiveness, and nuanced antibiotic stewardship recommendations, reflecting accumulating evidence from large-scale trials.

Despite these advances, sepsis remains one of the leading causes of death worldwide, accounting for approximately 11 million deaths annually. The central clinical question persists: how do we reliably identify sepsis early and intervene rapidly enough to prevent the cascade of organ dysfunction that drives mortality? This lesson dissects the pathophysiology, diagnostic criteria, and evidence-based management strategies essential for mastering sepsis on the USMLE Step 2 and in clinical practice.

SECTION 2

Core Principles & Definitions

The Sepsis-3 definitions fundamentally reframed how clinicians conceptualize sepsis. Rather than viewing it merely as infection plus systemic inflammation, the current paradigm emphasizes that sepsis is fundamentally about organ dysfunction driven by a maladaptive host response. Understanding the core principles below is essential for both examination performance and clinical reasoning.

Sepsis (Sepsis-3)

Life-threatening organ dysfunction caused by a dysregulated host response to infection. Operationally defined as a suspected infection with an acute increase in SOFA score ≥ 2 points from baseline.

Septic Shock

A subset of sepsis with profound circulatory, cellular, and metabolic abnormalities. Clinically identified by the need for vasopressors to maintain MAP ≥ 65 mmHg and a serum lactate > 2 mmol/L despite adequate volume resuscitation.

qSOFA (Quick SOFA)

Bedside screening tool: altered mentation (GCS < 15), systolic BP ≤ 100 mmHg, and respiratory rate ≥ 22/min. A score ≥ 2 prompts further assessment for organ dysfunction. Not a diagnostic criterion, but a prognostic screen.

Dysregulated Host Response

The pathologic hallmark: pro-inflammatory cytokines (TNF-α, IL-1, IL-6) and anti-inflammatory mediators (IL-10) are released simultaneously, leading to endothelial damage, microvascular thrombosis, and immune paralysis rather than effective pathogen clearance.

Hour-1 Bundle

Surviving Sepsis Campaign mandates within 1 hour: measure lactate, obtain blood cultures before antibiotics, administer broad-spectrum antibiotics, begin 30 mL/kg crystalloid for hypotension or lactate ≥ 4, and start vasopressors if hypotensive during/after fluid resuscitation.

✦ KEY TAKEAWAY

Think of the immune system in sepsis like a fire department that, while responding to a house fire, accidentally floods the entire neighborhood. The initial pathogen triggers an inflammatory response, but the collateral damage from the dysregulated immune response — endothelial injury, microvascular thrombosis, distributive shock — is what causes organ failure and death, not the infection alone. That is why Sepsis-3 centers its definition on organ dysfunction rather than on the presence of bacteria in the blood.

SECTION 3

Pathophysiology of Sepsis — Visual Overview

This diagram traces the pathophysiologic cascade from the initial infection source through pattern recognition receptor (PRR) activation, the ensuing cytokine storm, and the three major downstream pathways — endothelial injury, coagulopathy, and pathologic vasodilation — that converge to produce multi-organ dysfunction, the defining feature of sepsis under Sepsis-3 criteria.

The cascade begins when pathogen-associated molecular patterns (PAMPs) — such as lipopolysaccharide from gram-negative bacteria or lipoteichoic acid from gram-positive organisms — engage toll-like receptors (TLRs) on innate immune cells. This triggers NF-κB signaling and the release of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. In sepsis, this inflammatory response becomes self-amplifying and injurious. Endothelial glycocalyx degradation increases capillary permeability, leading to interstitial edema and effective hypovolemia. Simultaneously, inducible nitric oxide synthase (iNOS) activation generates excessive nitric oxide, producing profound vasodilation and hypotension. The coagulation system is activated via tissue factor expression on monocytes and endothelium, resulting in disseminated intravascular coagulation (DIC) and microvascular thrombosis that impairs oxygen delivery to tissues. The convergence of these three pathways — capillary leak, distributive shock, and microvascular occlusion — drives the multi-organ dysfunction that defines sepsis.

SECTION 4

Scoring Systems & Diagnostic Framework

Accurate and rapid identification of sepsis depends on validated scoring systems that quantify the degree of organ dysfunction. The two principal tools in current practice are the SOFA score for diagnosis and prognosis, and the qSOFA score for rapid bedside screening outside the ICU. Understanding the components and clinical application of each is essential for both boards and clinical practice.

SOFA Score Components

Sequential Organ Failure Assessment (SOFA) Score — A ≥ 2-point acute increase from baseline indicates sepsis.

Organ System	Parameter	Score 0	Score 1	Score 2	Score 3–4
Respiration	PaO₂/FiO₂	≥ 400	< 400	< 300	< 200 (with vent) / < 100
Coagulation	Platelets (×10³/µL)	≥ 150	< 150	< 100	< 50 / < 20
Liver	Bilirubin (mg/dL)	< 1.2	1.2–1.9	2.0–5.9	6.0–11.9 / ≥ 12
Cardiovascular	MAP / Vasopressors	MAP ≥ 70	MAP < 70	Dopa ≤ 5 or dobutamine	Dopa > 5 / Epi / Norepi
CNS	Glasgow Coma Scale	15	13–14	10–12	6–9 / < 6
Renal	Creatinine (mg/dL) or UOP	< 1.2	1.2–1.9	2.0–3.4	3.5–4.9 / < 500 mL/d

qSOFA Bedside Screen

QUICK SOFA (qSOFA)

qSOFA = (RR ≥ 22) + (SBP ≤ 100) + (Altered Mentation)

Each criterion scores 1 point. A score ≥ 2 suggests organ dysfunction and warrants full SOFA assessment. RR = respiratory rate, SBP = systolic blood pressure, Altered mentation = GCS < 15.

SEPTIC SHOCK CRITERIA

Septic Shock = Sepsis + Vasopressor Requirement (MAP ≥ 65) + Lactate > 2 mmol/L

Both criteria must be met despite adequate fluid resuscitation. Septic shock carries an in-hospital mortality rate exceeding 40%.

⚡ High-Yield Board Pearl

SIRS criteria (temp > 38°C or < 36°C, HR > 90, RR > 20 or PaCO₂ < 32, WBC > 12,000 or < 4,000 or > 10% bands) are no longer part of the Sepsis-3 definition but remain clinically useful as screening tools. For USMLE Step 2, know both the legacy SIRS-based criteria and the current SOFA-based Sepsis-3 definitions.

SECTION 5

Management — The Sepsis Bundle & Evidence-Based Interventions

Effective sepsis management hinges on rapid, protocolized care delivered in time-sensitive bundles. The Surviving Sepsis Campaign (SSC) has iteratively refined these bundles based on evidence from landmark trials. Each hour of delay in antibiotic administration after the onset of septic shock has been associated with a measurable increase in mortality. The current framework emphasizes a one-hour bundle initiated from the time of sepsis recognition, though in practice, many elements are pursued simultaneously.

The sepsis management algorithm illustrates the Hour-1 Bundle elements (lactate, cultures, antibiotics, crystalloid) followed by iterative reassessment of volume status and perfusion. Persistent hypotension triggers vasopressor initiation, with norepinephrine as the first-line agent and vasopressin or stress-dose hydrocortisone for refractory shock.

Key Pharmacologic Interventions

Antibiotics: Administer broad-spectrum coverage within 1 hour. Common empiric regimens include piperacillin-tazobactam, meropenem, or cefepime ± vancomycin if MRSA is suspected. De-escalate based on culture data and clinical response.
Norepinephrine: First-line vasopressor for septic shock, acting primarily via α₁ receptors to increase SVR and MAP. Target MAP ≥ 65 mmHg.
Vasopressin: Added as a second-line agent (typically 0.03 U/min) if MAP remains below target on norepinephrine; may allow catecholamine dose reduction.
Corticosteroids: IV hydrocortisone 200 mg/day is recommended for septic shock refractory to fluids and vasopressors. The ADRENAL and APROCCHSS trials inform current practice.
Source Control: Drainage of abscesses, debridement of necrotic tissue, removal of infected devices — source control should be achieved as rapidly as possible, ideally within 6–12 hours of identification.

SECTION 6

Worked Example — Recognizing & Managing Sepsis

Consider the following clinical scenario: A 68-year-old woman with a history of type 2 diabetes and recurrent UTIs presents to the emergency department with fever, confusion, and hypotension. Her vitals are: T 39.2°C, HR 112 bpm, RR 26 breaths/min, BP 88/52 mmHg, SpO₂ 94% on room air. Labs reveal WBC 18,200, lactate 4.8 mmol/L, creatinine 2.4 mg/dL (baseline 0.9), platelets 110,000, and bilirubin 1.8 mg/dL.

Step-by-Step Clinical Reasoning

Step 1 — Calculate qSOFAAssess the three qSOFA criteria: (1) RR ≥ 22 → Yes (RR = 26), (2) SBP ≤ 100 → Yes (SBP = 88), (3) Altered mentation → Yes (confused, GCS < 15). The patient scores 3 out of 3 on qSOFA, prompting immediate concern for sepsis.

qSOFA = 3 → High suspicion for sepsis

Step 2 — Calculate Acute SOFA ChangeEvaluate each SOFA component: Respiration — PaO₂/FiO₂ not yet measured but SpO₂ 94% on RA suggests mild impairment (≈ score 1). Coagulation — Platelets 110,000 (score 1). Liver — Bilirubin 1.8 (score 1). Cardiovascular — MAP = (88 + 52 + 52)/3 ≈ 64 mmHg, so MAP < 70 (score 1), and she is hypotensive. CNS — Confused (GCS ≈ 13, score 1). Renal — Creatinine 2.4, baseline 0.9 (score 2). Total acute SOFA increase ≈ 7 points from a presumed baseline of 0, well above the ≥ 2-point threshold.

ΔSOFA ≈ 7 → Meets Sepsis-3 criteria

Step 3 — Initiate Hour-1 BundleLactate is already drawn (4.8 mmol/L). Obtain two sets of blood cultures from separate sites plus a urine culture given UTI history. Administer broad-spectrum antibiotics immediately — given the urinary source, ceftriaxone or piperacillin-tazobactam is appropriate. Begin IV crystalloid (balanced solution or normal saline) at 30 mL/kg. For a 70 kg patient, this equals approximately 2,100 mL, administered as rapidly as tolerated within the first hour.

30 mL/kg × 70 kg = 2,100 mL crystalloid bolus

Step 4 — Reassess & EscalateAfter the initial fluid bolus, the patient's BP improves to 92/58 but MAP remains < 65 mmHg (MAP ≈ 69 mmHg). She is not yet demonstrating adequate perfusion. Reassess fluid responsiveness using passive leg raise, pulse pressure variation, or point-of-care echo. If MAP remains below 65 despite adequate resuscitation, initiate norepinephrine as the first-line vasopressor.

Persistent hypotension → Start norepinephrine, target MAP ≥ 65 mmHg

Step 5 — Determine if Septic ShockThis patient requires vasopressors to maintain MAP ≥ 65 mmHg, and her lactate is 4.8 mmol/L (> 2 mmol/L) despite initial fluid resuscitation. She meets the Sepsis-3 criteria for septic shock. Repeat lactate in 2–4 hours to guide resuscitation; target a ≥ 10% decrease. Consider stress-dose hydrocortisone if shock is refractory, and obtain imaging to identify the source for potential intervention.

Septic Shock confirmed — Vasopressor-dependent + Lactate > 2 despite fluids

SECTION 7

SIRS vs. Sepsis-3 — Strengths, Limitations & Microbiology Considerations

The transition from SIRS-based to SOFA-based sepsis definitions represented a paradigm shift, but both frameworks have distinct strengths and weaknesses that are clinically and academically relevant. Additionally, understanding the common microbial etiologies and empiric antibiotic strategies is critical for boards.

Comparison of SIRS-based vs. SOFA-based sepsis definitions

Feature	SIRS-Based (Sepsis-1/2)	SOFA-Based (Sepsis-3)
Core Criteria	≥ 2 of 4 SIRS criteria + infection	SOFA ≥ 2-point acute increase + infection
Sensitivity	High — captures most infected patients	Moderate — may miss early sepsis without overt organ dysfunction
Specificity	Low — many non-infectious causes trigger SIRS (trauma, burns, pancreatitis)	Higher — focuses on organ dysfunction, more specific for poor outcomes
Prognostic Value	Poor predictor of mortality	Strong predictor of in-hospital mortality (≥ 10% with SOFA ≥ 2)
Bedside Utility	Easy to calculate at bedside	Full SOFA requires labs; qSOFA serves as bedside proxy
Limitation	1 in 8 sepsis patients never meet SIRS criteria ("SIRS-negative sepsis")	qSOFA has poor sensitivity in ED settings; not a replacement for clinical judgment

Common Microbial Etiologies

Common sources and empiric antibiotic coverage in sepsis

Source	Common Organisms	Empiric Antibiotic Choice
Pulmonary	S. pneumoniae, H. influenzae, Legionella, MRSA (if ventilator-associated), Pseudomonas	Ceftriaxone + azithromycin (CAP); Pip-tazo or meropenem + vancomycin (HAP/VAP)
Urinary	E. coli, Klebsiella, Proteus, Enterococcus	Ceftriaxone or fluoroquinolone; pip-tazo if complicated
Intra-abdominal	E. coli, Bacteroides fragilis, Enterococcus, polymicrobial	Pip-tazo or meropenem; metronidazole + cephalosporin
Skin/Soft Tissue	S. aureus (MSSA/MRSA), Group A Streptococcus, polymicrobial (diabetic foot)	Vancomycin + pip-tazo; clindamycin for necrotizing fasciitis (anti-toxin)
Line-Related	Coagulase-negative staph, S. aureus, Candida, Gram-negatives	Vancomycin ± antifungal; remove the line

✦ KEY TAKEAWAY

Think of empiric antibiotic selection like casting a wide net when you know fish are present but not the species. You want to cover the most likely organisms based on the suspected source, then narrow the spectrum as culture data returns — this is antibiotic stewardship, and it reduces resistance selection pressure while maintaining effective treatment.

SECTION 8

Advanced Concepts — Hemodynamic Phenotypes & Emerging Therapies

While Step 2 focuses on core management principles, a working knowledge of advanced hemodynamic concepts and emerging therapeutic strategies provides context for evolving clinical practice and is increasingly tested on boards. Sepsis is not a monolithic entity; emerging research has identified distinct hemodynamic phenotypes that may respond differently to standardized resuscitation protocols.

Standard vs. advanced/emerging approaches in sepsis management

Concept	Core Sepsis Management	Advanced / Emerging Approach
Fluid Resuscitation	30 mL/kg crystalloid bolus within 1 hour for all sepsis with hypotension or lactate ≥ 4	CLOVERS trial (2023): restrictive vs. liberal fluid strategy showed no mortality difference; trend toward individualized, dynamic fluid assessment using PLR, PPV, or POCUS
Vasopressor Selection	Norepinephrine 1st line → vasopressin 2nd line → epinephrine or phenylephrine 3rd line	Angiotensin II (Giapreza) approved for refractory vasoplegia; may have a role in high-renin phenotypes
Corticosteroids	Hydrocortisone 200 mg/day for refractory septic shock	ADRENAL trial: no mortality benefit but faster shock reversal; APROCCHSS trial: mortality benefit with hydrocortisone + fludrocortisone; practice varies by institution
Biomarkers	Lactate for resuscitation guidance; procalcitonin for antibiotic de-escalation	Presepsin, mid-regional pro-adrenomedullin (MR-proADM), and IL-6 under investigation for earlier detection and phenotyping
Immunomodulation	Not part of standard bundles	Immune paralysis phase: trials of GM-CSF, IFN-γ, and checkpoint inhibitors (anti-PD-1) to reverse sepsis-induced immunosuppression

The recognition that sepsis progresses through distinct immunologic phases — an initial hyperinflammatory phase followed by a compensatory anti-inflammatory response syndrome (CARS) with immune paralysis — has fundamental implications for therapy. Many patients who survive the initial hemodynamic insult succumb to secondary infections during the immunosuppressed phase. Future therapies will likely be guided by real-time immune phenotyping, moving beyond a "one-size-fits-all" approach to precision medicine in critical care.

📋 USMLE Board Tip

For Step 2, focus on the standard Hour-1 bundle and first-line pharmacology. However, be aware that balanced crystalloids (lactated Ringer's) are increasingly preferred over normal saline based on the SMART trial, which demonstrated reduced composite renal outcomes. The CLOVERS trial's implication — that fixed-volume resuscitation may be replaced by dynamic assessment — is emerging board content.

SECTION 9

Practice Problems

PROBLEM 1 — CONCEPTUAL

A 55-year-old man presents with a suspected urinary tract infection. He has a temperature of 38.6°C, heart rate of 95, respiratory rate of 18, and WBC of 14,000. He is alert and oriented with a blood pressure of 125/78. Does this patient meet criteria for sepsis under the Sepsis-3 definition? Explain your reasoning.

PROBLEM 2 — BASIC CALCULATION

A 72-year-old woman in septic shock weighs 80 kg. Per the Surviving Sepsis Campaign guidelines, what is the initial crystalloid fluid bolus she should receive, and within what time frame? If her lactate is initially 5.2 mmol/L and repeat lactate 2 hours later is 4.3 mmol/L, has she met the lactate clearance goal?

PROBLEM 3 — INTERMEDIATE

A 60-year-old man with community-acquired pneumonia is admitted to the ICU. He is intubated with PaO₂/FiO₂ of 180, platelets 90,000, bilirubin 2.5, creatinine 3.0 (baseline 1.0), GCS 11 (sedated), and requires norepinephrine at 0.15 µg/kg/min to maintain MAP of 66 mmHg. Calculate his SOFA score and determine if he meets criteria for sepsis and/or septic shock.

PROBLEM 4 — APPLIED

A 45-year-old immunocompromised man (on chemotherapy for lymphoma) presents with fever 39.5°C, rigors, and a tunneled central venous catheter in place. Blood pressure is 85/50 mmHg, HR 120, lactate 3.8 mmol/L. Blood cultures are drawn and empiric antibiotics started. After 2 liters of crystalloid, his BP is 90/55 and lactate is 3.5. Describe your next management steps, including vasopressor choice, steroid considerations, and source control.

PROBLEM 5 — CRITICAL THINKING

A colleague argues that the Hour-1 bundle mandate to give 30 mL/kg crystalloid to all septic patients with hypotension is outdated, citing the CLOVERS trial. Another colleague insists that deviating from the SSC bundle increases mortality. Critically evaluate both positions using evidence from key trials (CLOVERS, SMART, PROCESS, ARISE), and propose a nuanced approach to fluid management in sepsis that balances protocol adherence with individualized care.

SUMMARY

Sepsis & Severe Infection — Key Concepts Review

Sepsis is defined under Sepsis-3 as life-threatening organ dysfunction caused by a dysregulated host response to infection, operationalized as an acute SOFA score increase ≥ 2. Septic shock is the subset requiring vasopressors for MAP ≥ 65 with lactate > 2 mmol/L despite adequate resuscitation, carrying mortality exceeding 40%. The qSOFA screen (altered mentation, SBP ≤ 100, RR ≥ 22) identifies patients at risk outside the ICU.

Management is driven by the Hour-1 Bundle: measure lactate, obtain blood cultures before antibiotics, administer broad-spectrum antibiotics within one hour, initiate 30 mL/kg crystalloid for hypotension or elevated lactate, and start norepinephrine as the first-line vasopressor if hypotension persists. Source control must be pursued aggressively, and resuscitation is guided by dynamic reassessment of perfusion markers including lactate clearance, urine output, and hemodynamic responsiveness. Understanding the pathophysiologic cascade — from PAMPs and cytokine release through endothelial injury, coagulopathy, and vasodilation — provides the mechanistic foundation for every therapeutic intervention.